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Abstract
Purpose: To test feasibility and safety of clinical usage of Flattening Filter Free (FFF) beams for delivering ablative
stereotactic body radiation therapy (SBRT) doses to various tumor sites, by means of Varian TrueBeam™ (Varian
Medical Systems).
Methods and Materials: Seventy patients were treated with SBRT and FFF: 51 lesions were in the thorax (48
patients),10 in the liver, 9 in isolated abdominal lymph node, adrenal gland or pancreas. Doses ranged from 32 to
75 Gy, depending on the anatomical site and the volume of the lesion to irradiate. Lung lesions were treated with
cumulative doses of 32 or 48 Gy, delivered in 4 consecutive fractions. The liver patients were treated in 3 fractions
with total dose of 75 Gy. The isolated lymph nodes were irradiated in 6 fractions with doses of 45 Gy. The
inclusion criteria were the presence of isolated node, or few lymph nodes in the same lymph node region, in
absence of other active sites of cancer disease before the SBRT treatment.
Results: All 70 patients completed the treatment. The minimum follow-up was 3 months. Six cases of acute
toxicities were recorded (2 Grade2 and 2 Grade3 in lung and 2 Grade2 in abdomen). No patient experienced acute
toxicity greater than Grade3. No other types or grades of toxicities were observed at clinical evaluation visits.
Conclusions: This study showed that, with respect to acute toxicity, SBRT with FFF beams showed to be a feasible
technique in 70 consecutive patients with various primary and metastatic lesions in the body.
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Introduction
In case of tumors at early stage, or in case of isolated
small metastases, stereotactic body radiation therapy
(SBRT) has proved to be a safe and feasible treatment
approach, as demonstrated by the tumor response and
local control rates in selected series [1].
Improvements in screening intensification and in
management techniques have reached high levels of
accuracy so that it is possible to detect tumors at rather
early stages. The paradigm of the usefulness of SBRT in
localized primary tumors is early non small cell lung
cancer (NSCLC). Highly focused doses of 60-66 in three
fractions with SBRT to NSCLC in early stages, achieve
an actuarial 2-year local control of 95%[2]. The position
of the lesion is a limitation in dose escalation: although
less than 20% of patients showed high-grade toxicity,
toxicity greater than grade 3 were more frequent in
patients with tumors proximal to the bronchial tree or
central chest region [3]. In a retrospective review, Onishi
et al: analyzed a large number of SBRT treatments from
a Japanese multi-institutional database showing that
SBRT is safe and promising as a radical treatment for
operable Stage I NSCLC [4]. When the effective biologic
dose was greater than 100 Gy, the survival rate was
higher.
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schemes and tailored drugs are improving significantly
survival of cancer patients. In this scenario, it is possible
to perform aggressive treatment of oligometastatic dis-
ease with curative-intent [5].
Promising studies, are exploring the safety and feasi-
bility of SBRT in abdominal and pelvic sites [6-13].
Rusthoven showed that, in patients with metastatic liver
lesions, it is possible to deliver safely 60 Gy, in three
fractions [13].
As a consequence, large groups of patients with primary
or metastatic lesions can deserve SBRT, as curative
approach and improvements in precision and accuracy are
advisable to allow safe prescription of more ablative doses.
Recently, two new technological platforms have been
made available to clinical practice. Firstly, Volumetric
Modulated Arc Therapy (VMAT) in its RapidArc
® format,
allowed to reduce significantly the time needed to deliver
complex intensity modulated plans, allowing to treat hypo-
fractionated regimes within few minutes [14-17]). Sec-
ondly, there has been increasing attention into the clinical
use of linear accelerators (LINAC) with photon beams
generated without usage of the flattening filter [18-24]. It
seems possible to expect a reduction of out-of-field dose
when flattening filter free (FFF) beams are used. This is
mainly due to reduced head scatter and residual electron
contamination. FFF beams should therefore lead to
reduced peripheral doses and patients may benefit by
decreased exposure of normal tissue to scattered doses
outside the field. Removal of the flattening filter implies
also the possibility to deliver treatments with higher dose
rates, up to factor 4 at 10 MV, and with a much higher
dose per pulse. This, beside further improving time effi-
ciency for delivery, might have subsequent potential radio-
biology implications, now still unclear and deserving
dedicated investigations. While research in the physics
domain for FFF beams is increasing, there are very few
clinical data where FFF beams are applied in clinical prac-
tice, particularly in SBRT treatments.
Over the last few years the clinical introduction of
RapidArc
® in SBRT was explored and, to test the feasibil-
ity and safety of combining this technique with FFF
beams, a group of patients was treated with ablative
SBRT doses to various anatomical tumor sites, by means
of the recently introduced Varian TrueBeam™ system
(Varian Medical Systems, Palo Alto, CA, USA)
[15,16,24,25]. The evaluation of the role of FFF beams in
reducing involvement of organs at risk while preserving
adequate target coverage is not aim of the present study.
Materials and methods
Population of study
This is a prospective study and it was approved by the
Institution. Between September and December 2010, a
total of 123 patients were treated with the TrueBeam™
newly installed. Seventy out of 123, were treated with
SBRT and FFF beams (SBRT-FFF group). In this group,
51 lesions were in the thorax (48 patients) and 19 in the
abdomen: 10 liver, 4 isolated abdominal lymphnode
metastases, 3 adrenal gland, 2 pancreas. Table 1 sum-
marizes demographic data. Patients will be stratified
into three groups: lung, abdominal and liver cases.
Protocols: inclusion criteria and dose prescription
Prescription doses ranged from 32 to 75 Gy (mean
dose to target volume), depending on the site and on
the volume of the lesions. Good performance status
and good compliance to radiation treatment were
requested in all patients. Lung lesions (primary early
NSCLC and oligometastatic cases) were treated with
c u m u l a t i v ed o s e so f3 2o r4 8G y ,d e l i v e r e di n4c o n s e -
cutive daily fractions. The dose of 32 Gy was pre-
scribed to lesions located centrally or at a distance < 2
cm from the carena and/or to lesion with maximum
diameter > 3 cm. In the remaining cases, a dose of 48
Gy was prescribed.
The ten liver patients, were treated for metastatic
lesions in 3 fractions up to 75 Gy. Eligible patients met
these criteria: inoperable or medically unsuitable for
resection, maximum tumour diameter < 6 cm, one to
three hepatic lesions. The 4 isolated lymph nodes, the
adrenal gland and pancreas cases were irradiated in 6
fractions up to 45 Gy. The inclusion criteria were the
presence of isolated or few lymph nodes in the same
Table 1 Main characteristics of patients cohort
Gender
Male 46 (66%)
Female 24 (34%)
Age (y)
Median 65
Range 39-89
Primary site
Lung 34(48%)
Colon 10(14%)
Breast 2(3%)
Pancreas 2 (3%)
Uterus 1 (1,5%)
Sarcoma 6 (9%)
Stomach 3 (4, %)
Prostate 1(1,5%)
Liver 4(6%)
Endometrial 1(1,5%)
Melanoma 1(1,5%)
Unknown 5 (7%)
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cancer disease.
CT scans for planning were acquired for all patients
positioned supine with their arms above the head and
immobilized by means of a thermoplastic body mask
(including a styrofoam block for abdominal compression
to minimize internal organ motion in abdominal cases).
Contrast free and Contrast-enhanced planning CT scans
were acquired in free breathing mode at 3 mm slice
thickness.
The clinical target volume (CTV) included macro-
scopic and microscopic disease on CT as well as on
PET if available. The planning target volume (PTV) was
generated by taking into account both the internal mar-
gin (IM) and the set-up margin (SM). IM depends on
intra- and inter-fraction organ motion (expected to be
not significant in a short course of radiation for retro-
peritoneal nodes adjacent to spine and large vessels
while it may be relevant for lung, pancreatic and liver
tumours) [26-30]. Since SM was minimised by the cone-
beam CT (CBCT) verification of set up variations, the
overall standardised CTV-PTV margin was prescribed as
6-15 mm in the cranial-caudal axis and 3-8 mm in the
anterior-posterior and lateral axes. For 70% of the lung
patients, 4 DCT retrospective scans were acquired for
planning purpose and PTV was defined using smaller
margins, i.e. 5 mm isotropic in all directions.
Planning objectives to target coverage aimed to cover
PTV with 95% of the prescribed dose (reduced to 67%
for few liver metastases cases whenever it was impossi-
ble to respect dose constraints to organs at risk). The
main organs at risk (OAR) considered, depending on
the treatment site, were: lungs, oesophagus, spinal cord,
heart, kidneys, stomach, duodenum, small bowel and
liver. Stomach, duodenum and small bowel were con-
toured when appropriate. For OARs, plans were
required to meet explicit objectives as follows: Spinal
cord: D0.1 cm3 <1 8G y( d o s el o w e rt h a n1 8G yt o ta
volume of 0.1 cm
3); V15 Gy < 35% for both kidneys (less
than 35% of the volume receiving 15 Gy), V36 Gy <3 %
for stomach and small bowel, V15 Gy <( t o t a ll i v e r
volume minus 700 cm
3, i.e. at least 700 cm
3 of liver
should receive less than 15 Gy) for liver. In addition
D0.5 cm3 < 30 Gy for stomach and small bowel was con-
sidered as a secondary objective. For lungs V5G y< 30%,
V10 Gy < 12% V20 Gy < 10%. For heart and for oesopha-
gus no explicit planning objectives were applied.
SBRT procedure
TrueBeam™ is a new LINAC designed to deliver flat-
tened, as well as flattening filter-free (FFF) photon
beams. In TrueBeam™, many key elements including the
waveguide system, carousel assembly, beam generation,
and monitoring control system differ from the preceding
LINAC series as described in [24].
All patients were treated with RapidArc
® with 6 (11
cases) or 10 MV (59 cases) FFF beams. Energy selection
was based on achievable plan quality. The maximum
dose rate enabled for FFF beams was 1400 MU/min for
6 MV and 2400 MU/min for 10 MV [30]. RapidArc
®
plans were individually designed using full or partial sin-
gle or multiple arcs chosen to obtain the best adherence
to planning objectives for each patient. All dose distri-
butions were computed with the Analytical Anisotropic
Algorithm (AAA, version 8.9 [31]) implemented in the
Eclipse planning system with a calculation grid resolu-
tion of 2.5 mm.
A feature of TrueBeam™, applied to all the patients in
the study, is the so-called ‘jaws tracking’ mode. In this
mode, the main jaws of the LINAC are dynamically
moved by the control system to the minimum aperture
needed to cover target projection and to maximize
organs at risk sparing at each gantry projection.
Treatment was delivered in 3 to 6 consecutive work-
ing days, with the patient on a 3-hour fast to avoid
gross displacement of stomach and bowel. Treatment
delivery included stereotactic frame localization and
CBCT in the first session aiming at a preliminary iso-
centre positioning while for following fractions, patient
set-up was realised by means of CBCT image guidance
with, eventually, on-line couch adjustment at each frac-
tion. Image matching was performed on bones and,
when visible, on tumors and other soft tissue structures
(e.g. main blood vessels).
Evaluation of dosimetric and technical data
For each group of patients, technical parameters of
delivery were scored in terms of number of arcs, total
number of monitor units (MU), monitor units per Gy
(MU/Gy), total beam on time. Dosimetric quality of
treatments was measured from dose volume histogram
(DVH) analysis. For PTV, the target coverage (mean,
D1%,D 95%,V 67%,V 80%,V 95%,V 107%), the homogeneity
(Standard Deviation) and the conformity for PTV
(CI95%) were reported. CI was defined as the ratio
between the volume of patient irradiated at 95% of the
prescribed dose and the PTV volume [32]. For OARs,
the mean dose, the maximum dose (Dxcm3)a n da p p r o -
priate values of VxGy (volume receiving at least xGy)
were scored.
Evaluation of clinical data
Clinical evaluations were planned on first day of treat-
ment, before SBRT-FFF session (visit 0); visit 1 during
the course of the treatment; visit 2 at the end of the last
session; visit 3 within 60-90 days from the end of the
Scorsetti et al. Radiation Oncology 2011, 6:113
http://www.ro-journal.com/content/6/1/113
Page 3 of 8treatment. Unscheduled visits could be performed if
necessary.
Acute radiation induced toxicities were scored accord-
ing to NCI Common Terminology Criteria for Adverse
Events (CTCAE version 3.0) [33].
A first assessment of treatment outcome, although
obviously very early, was performed at first and second
follow up visits and will be reported in terms of degree
of response.
Results
Dosimetric and technical data
Figure 1 illustrates examples of dose distributions of
lung, abdominal and liver patients with display of an
axial, sagittal and coronal plane. Figure 2 present aver-
age cumulative dose volume histograms for PTV and all
organs at risk for the entire cohort of patients and for
the three sub groups.
Table 2 shows results from DVH analysis for target
volumes, stratified according to localization. Table 3
contains the results for OARs.
Table 4 summarizes the technical delivery parameters.
Target coverage (D95%)a n dh o m o g e n e i t yw e r es i m i l a r
to those of abdomen SBRT treatments, published by our
group, characterized by high degree of conformality and
modest target overdosage (V107%)[15]. For OARs, it was
possible to respect planning objectives in most of the
cases, also in the case of ipsilateral lung with a mean
dose smaller than 5 Gy and V5G y< 30%.
Analysis of the technical delivery parameters showed
that the availability of extended dose rate with FFF
beams was fully exploited by the RapidArc
® technique
with an average DR of 1500 and range spanning from
about 300 MU/min to a maximum of 2400 MU/min
(leading to a relatively wide range of MU/deg from
about 1 to about 17). As a consequence, although the
dose per fraction reached 25 Gy, the beam on time, was
kept very small with a range from < 1 min to 5 min.
Clinical Data
All 70 SBRT-FFF patients completed the treatment, as
programmed. The minimum follow-up was 3 months.
Figure 1 Examples of dose distributions for the three groups of patients. Colourwash scale is from 20 to 50 Gy for the lung and the
abdominal cases and from 35 to 80 Gy for the liver case.
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and 2 Grade 3 in lung and 2 Grade 2 in abdomen). No
patient experienced acute toxicity greater than Grade 3.
No other types or grades of toxicities were experienced
at clinical evaluations.
In 55 out of 70, early clinical outcome was assessable
at first diagnostic evaluation with PET and/or CT: com-
plete response was achieved in 10 patients, partial
response was in 26, and in 13 disease remained stable.
Progression was found in 6 irradiated lesions.
Figure 2 Average cumulative DVH for OARs and PTV for all patients and stratified in the three groups.
Table 2 Summary of dose volume histogram analysis for PTV and healthy tissue
Parameter All Lung Liver Abdomen
PTV
Volume [cm
3] 78 ± 78 55 ± 55 146 ± 116 115 ± 82
Mean dose [%] 101.0 ± 2.9 101.2 ± 1.0 100.6 ± 1.6 100.3 ± 0.5
St. Dev. [%] 2.7 ± 0.6 2.9 ± 0.5 2.3 ± 0.8 2.1 ± 0.6
D1% [%] 106.0 ± 1.8 106.8 ± 1.5 104.3 ± 1.6 104.4 ± 1.4
D95% [%] 96.2 ± 1.0 96.1 ± 0.9 96.2 ± 1.5 96.4 ± 0.8
V95% [%] 97.3 ± 1.9 97.1 ± 1.7 97.2 ± 3.0 97.9 ± 1.5
V107 [%] 1.5 ± 5.1 2.1 ± 6.0 0.1 ± 0.2 0.0 ± 0.1
Healthy tissue
Volume [cm
3] 30660 ± 8928 29283 ± 7493 36232 ± 13301 31510 ± 8805
Mean [Gy] 1.2 ± 0.7 1.1 ± 0.8 1.4 ± 0.3 1.3 ± 0.6
V10 Gy [%] 3.3 ± 2.7 3.0 ± 3.0 4.0 ± 1.3 3.9 ± 2.4
CI95% 1.2 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 1.2 ± 0.3
Dose Int. [Gy*cm
3*10
4] 3.5 ± 2.1 3.1 ± 2.0 5.0 ± 2.1 4.1 ± 1.8
VxGy: volume receiving at least × Gy. Dx%: dose received by at least x% of the volume. CI: Conformity Index
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In the current study we report on the treatment of a
group of patients undergoing SBRT with RapidArc
®
technique in combination with flattening filter free
photon beams with the new TrueBeam™ LINAC. The
rationale of the use of FFF beams for delivering SBRT
doses, is the potential possibility to deliver high ablative
doses faster and more precisely, due to decreased out-
of-field dose and to increased dose rate removing flat-
tening filter [24]. In addition, the time factor linked to
the very high dose rates available, suggests that FFF
beams might be of interest also in the case of respira-
tory gated treatments where the trade-off of low duty
cycle might be efficiently compensated. Another possible
and relatively obvious immediate advantage of high dose
rate of FFF beams is linked to the potential reduction of
intra-fraction motion, due to the reduction of total ses-
sion treatment time. All these aspects were not directly
addressed in the present study. The present study was
limited to a more primordial aim: the demonstration of
the clinical feasibility of SBRT treatments with FFF
beams, the demonstration of short term safety of these
Table 3 Summary of dose volume histogram analysis for
organs at risk
Parameter All Lung Liver Abdomen
Ipsilateral Lung
Volume
[cm
3]
1814.5 ±
619.0
1861.9 ±
610.5
1686.4 ±
797.2
1407.2 ±
76.1
Mean [Gy] 4.4 ± 3.0 4.9 ± 2.8 3.1 ± 3.1 0.2 ± 0.0
V5G y[%] 24.6 ± 18.3 27.6 ± 17.6 16.1 ± 17.0 0.0 ± 0.0
V10 Gy [%] 15.5 ± 12.6 17.4 ± 12.3 9.5 ± 11.8 0.0 ± 0.0
V20 Gy [%] 5.8 ± 4.8 6.6 ± 4.6 3.3 ± 5.4 0.0 ± 0.0
Contralateral Lung
Volume
[cm
3]
1703 ± 629 1774 ± 615 1352 ± 765 1484 ± 335
Mean [Gy] 1.6 ± 2.1 1.8 ± 2.2 1.0 ± 0.6 0.2 ± 0.1
V5G y[%] 7.0 ± 14.3 8.0 ± 15.7 3.8 ± 3.5 0.0 ± 0.1
V10 Gy [%] 2.7 ± 8.3 3.2 ± 9.2 0.1 ± 0.3 0.0 ± 0.0
V20 Gy [%] 0.9 ± 2.9 1.1 ± 3.2 0.0 ± 0.0 0.0 ± 0.0
Spinal cord
Volume
[cm
3]
65 ± 35 61 ± 36 76 ± 33 78 ± 28
D0.1 cm3
[Gy]
9.9 ± 5.5 10.2 ± 6.1 9.4 ± 3.1 8.8 ± 4.9
D1% [Gy] 9.0 ± 4.5 9.1 ± 4.8 8.8 ± 3.2 8.4 ± 4.8
Liver
Volume
[cm
3]
1473 ± 409 1735 ± 606 1546 ± 434 1266 ± 193
Mean [Gy] 8.0 ± 5.8 3.2 ± 2.6 12.9 ± 3.7 3.8 ± 3.6
V15 Gy [%] 18.8 ± 17.1 3.2 ± 2.2 33.7 ± 10.7 6.2 ± 8.9
Ipsilateral Kidney
Volume
[cm
3]
137 ± 38 - 134 ± 42 141 ± 38
Mean 5.0 ± 5.3 - 2.5 ± 2.4 7.8 ± 6.5
V15 Gy [%] 11.5 ± 20.0 - 2.2 ± 3.6 22.4 ± 26.0
Contralateral kidney
Volume
[cm
3]
139 ± 35 - 126 ± 37 151 ± 30
Mean [Gy] 2.7 ± 2.1 - 2.0 ± 1.1 3.4 ± 2.7
V15 Gy [%] 0.2 ± 0.7 - 0.0 ± 0.0 0.4 ± 1.0
Stomach
Volume
[cm
3]
104 ± 40 - 104 ± 40 -
Mean [Gy] 7.3 ± 2.8 - 7.3 ± 2.8 -
V36 Gy [%] 0.0 ± 0.0 - 0.0 ± 0.0 -
D0.5 cm3
[Gy]
20.6 ± 3.6 - 20.6 ± 3.6 -
Small Bowell
Volume
[cm
3]
1255 ± 569 - - 1255 ± 569
Mean [Gy] 4.1 ± 4.4 - - 4.1 ± 4.4
V36 Gy [%] 0.0 ± 0.0 - - 0.0 ± 0.0
D0.5 cm3
[Gy]
24.3 ± 13.0 - - 24.3 ± 13.0
Table 4 Main Technical features of delivered treatments
Mean ± SD Range
MU 2780 ± 1493 [629÷6734]
MU/Gy 283.6 ± 79.7 [164.1÷551.5]
MU/arc 1955 ± 1312 [315÷6099]
MU/deg 7.6 ± 4.3 [1.1÷17.2]
DR [MU/min] 1541 ± 621 [327÷2400]
Gantry speed [deg/s] 4.4 ± 1.6 [1.4÷6.0]
CP aperture [cm] 1.7 ± 0.8 [0.2÷4.4]
CP area [cm
2] 14.5 ± 10.4 [3.6÷55.2]
Arc length [deg] 258.5 ± 70.5 [158÷358]
Beam on time [min] 1.7 ± 0.7 [0.9÷4.4]
See Additional figure 1 and 2
Values are reported as averages over all patients, arcs and/or control points
Table 3 Summary of dose volume histogram analysis for
organs at risk (Continued)
Heart
Volume
[cm
3]
624 ± 190 629 ± 174 676 ± 298 365 ± 0.0
Mean [Gy] 4.3 ± 4.0 4.5 ± 4.2 4.3 ± 3.3 0.9 ± -0.0
D1% [Gy] 15.3 ± 9.6 15.9 ± 9.7 14.9 ± 10.7 6.1 ± -0.0
Oesophagus
Volume
[cm
3]
39 ± 43 32 ± 34 91 ± 86 -
Mean [Gy] 3.8 ± 2.9 3.8 ± 3.0 3.3 ± 3.7 -
D1% [Gy] 13.6 ± 7.9 13.9 ± 8.0 10.8 ± 10.2 -
VxGy: volume receiving at least × Gy. Dx%: dose received by at least x% of the
volume.
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metric and technical features of the treatments.
The objectives of this study were to evaluate feasibility
and safety of SBRT with FFF beams. Although, in hypo-
fractionated treatments performed the most significant
expected complications are usually the late effects, it is
remarkable that acute toxicity recorded in our popula-
tion of study was mild, confirming the feasibility and
safety of the clinical use of FFF beams in SBRT patients,
which are the end points of the current evaluation in
the study.
It is established that late effects are frequently related
to the intensity of acute toxicity and based only on this
statement we can expect promising long term tolerabil-
ity. On the other hand we have to consider that late
effects are mainly vascular mediate while the acute ones
are due to mitotic dead of replicating cells and the late
damage can also happen in absence of acute side effects.
Thus, a prolonged follow-up is needed to assess a good
long term tolerability of the treatment and it will be the
objective of our future analysis.
Although extremely preliminary, it is interesting that
a significant fraction of patients showed remission
already at two months, suggesting some interplay
between high dose per pulse of FFF beams and treat-
ment efficacy. Early local control was achieved in 89%
of the cases evaluated. It will be therefore important to
perform dedicated studies and to carefully follow
patients to assess if there is a radiobiological impact. It
was established that the effects of sublethal damage,
progression in cell cycle, and repopulation on survival
r a t e ,a c c o r d i n gt od o s er a t ea n dt h eb i o l o g i c a le f f e c t s
of radiation decreases as the dose rate decreases. Con-
cerning radiation doses delivered with high dose rates,
brachytherapy has been historically used safely and
with efficacy in various districts. In fact, modern
remote afterloader systems can deliver instantaneous
d o s er a t e sa sh i g ha s0 . 1 2G y / s e c( 4 3 0G y / h )a tad i s -
tance of 1 cm, resulting in treatment times of a few
minutes.
Although this wasn’tt h ee n dp o i n to ft h ec u r r e n t
study and longer follow up is needed to evaluate late
toxicity and clinical definitive response, this high early
response was not observed in previous investigations
and might be important, if confirmed, to correlate it to
the high dose intensity per pulse of FFF beams.
Conclusion
SBRT with FFF beams showed, under the acute toxicity
profile, to be a safe and feasible technique in 70 conse-
cutive patients with various primary and metastatic
lesions in the body. Initial clinical outcomes, in terms of
local control are promising. However in further research
it is necessary to assess definitive late toxicity and defi-
nitive tumor control outcome.
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